Aricept (donepezil) in Treatment Resistant Biolar (8/30/00)
Question:
This is more like it, Lynda. My doc was part of this study at MGH until she moved to Penn. Save the rehashed stuff for ASDM-M, ok? Thanks. Fred P.S. you left out the data that describes a few donepezil-induced manic episodes. That’s why it should be taken in the morning – it can cause insomnia. Also, it’s excellent for medication-induced cognitive impairment. – Hide quoted text — Show quoted text – Paper Burt_1999_Biol.Psychiatry_45_959 Donepezil in treatment-resistant bipolar disorder Authors Burt T, Sachs GS, Demopulos C Title Donepezil in treatment-resistant bipolar disorder Authors Burt T Sachs GS Demopulos C Source Biological Psychiatryry199945:959-64 PubMed : 99313955 Burt_1999_Biol.Psychiatry_45_959 BACKGROUND A considerable percentage of patients with bipolar disorder do not respond or do not tolerate conventional treatment Cholinesterase ChE inhibitors have been suggested to possess depressogenic and antimanic properties METHODS We report a case series of treatment-resistant bipolar patients n 11 to whom we administered the ChE inhibitor donepezil Four patients met criteria for current manic episode 5 for mixed episode 1 for hypomanic episode and 1 for major depressive episode Donepezil was added to current medication on an openlabel basis Ratings were based on a retrospective chart review RESULTS Of the 11 patients 6 54.5 demonstrated marked improvement improvement in CGI-S or 2 3 27.2 demonstrated slight improvement 1 did not respond and 1 did not tolerate the medication Among those patients who had marked improvement i.e responders n 6 improvement was observed within 2 weeks or less in 5 of them 83 Patients experienced only minor side effects CONCLUSIONS These pilot data suggest the efficacy and safety of donepezil in the treatment of bipolar disorder To our knowledge this is the first published report on the use of donepezil in the treatment of mood disorders Controlled randomized — Lynda — Lynda Paper Burt_1999_Biol.Psychiatry_45_959 Donepezil in treatment-resistant bipolar disorder Authors Burt T, Sachs GS, Demopulos C Title Donepezil in treatment-resistant bipolar disorder Authors Burt T Sachs GS Demopulos C Source Biological Psychiatryry199945:959-64 PubMed : 99313955 Burt_1999_Biol.Psychiatry_45_959 BACKGROUND A considerable percentage of patients with bipolar disorder do not respond or do not tolerate conventional treatment Cholinesterase ChE inhibitors have been suggested to possess depressogenic and antimanic properties METHODS We report a case series of treatment-resistant bipolar patients n 11 to whom we administered the ChE inhibitor donepezil Four patients met criteria for current manic episode 5 for mixed episode 1 for hypomanic episode and 1 for major depressive episode Donepezil was added to current medication on an openlabel basis Ratings were based on a retrospective chart review RESULTS Of the 11 patients 6 54.5 demonstrated marked improvement improvement in CGI-S or 2 3 27.2 demonstrated slight improvement 1 did not respond and 1 did not tolerate the medication Among those patients who had marked improvement i.e responders n 6 improvement was observed within 2 weeks or less in 5 of them 83 Patients experienced only minor side effects CONCLUSIONS These pilot data suggest the efficacy and safety of donepezil in the treatment of bipolar disorder To our knowledge this is the first published report on the use of donepezil in the treatment of mood disorders Controlled randomized — Lynda
Response:
Paper Burt_1999_Biol.Psychiatry_45_959 Donepezil in treatment-resistant bipolar disorder Authors Burt T, Sachs GS, Demopulos C Title Donepezil in treatment-resistant bipolar disorder Authors Burt T Sachs GS Demopulos C Source Biological Psychiatryry199945:959-64 PubMed : 99313955 Burt_1999_Biol.Psychiatry_45_959 BACKGROUND A considerable percentage of patients with bipolar disorder do not respond or do not tolerate conventional treatment Cholinesterase ChE inhibitors have been suggested to possess depressogenic and antimanic properties METHODS We report a case series of treatment-resistant bipolar patients n 11 to whom we administered the ChE inhibitor donepezil Four patients met criteria for current manic episode 5 for mixed episode 1 for hypomanic episode and 1 for major depressive episode Donepezil was added to current medication on an openlabel basis Ratings were based on a retrospective chart review RESULTS Of the 11 patients 6 54.5 demonstrated marked improvement improvement in CGI-S or 2 3 27.2 demonstrated slight improvement 1 did not respond and 1 did not tolerate the medication Among those patients who had marked improvement i.e responders n 6 improvement was observed within 2 weeks or less in 5 of them 83 Patients experienced only minor side effects CONCLUSIONS These pilot data suggest the efficacy and safety of donepezil in the treatment of bipolar disorder To our knowledge this is the first published report on the use of donepezil in the treatment of mood disorders Controlled randomized — Lynda — Lynda
